Two Sigma Advisers
LMNL

Two Sigma Advisers’s Liminal BioSciences Inc. Common Shares LMNL Stock Holding History

Two Sigma Advisers’s Portfolio LMNL Stock Details LMNL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,080
Closed -$5K – 2754
2022
Q3 		$5K Hold
1,080
– – ﹤0.01% 2501
2022
Q2 		$6K Hold
1,080
– – ﹤0.01% 2605
2022
Q1 		$11K Buy
+1,080
New +$10.1K ﹤0.01% 2696

Other funds holding LMNL

National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
ECM
Estabrook Capital Management New York $685M AUM 26.64% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Two Sigma Advisers's LMNL Position: Q4 2022 in Review

Two Sigma Advisers sold out of Liminal BioSciences Inc. Common Shares (LMNL) in Q4 2022, closing a stake of 1,080 shares — an estimated $5K sold.

Two Sigma Advisers first reported a position in LMNL in Q1 2022 and held it in 3 quarters. The position peaked at $11K in Q1 2022. 14 funds tracked by Wall St. Rank hold LMNL as of Q4 2022.

  • Two Sigma Advisers reported no remaining Liminal BioSciences Inc. Common Shares position as of Q4 2022 after selling out during the quarter.
  • Two Sigma Advisers sold 1,080 Liminal BioSciences Inc. Common Shares shares in Q4 2022, an estimated $5K.
  • Two Sigma Advisers first reported a position in Liminal BioSciences Inc. Common Shares in Q1 2022 and held it in 3 quarters.
  • Two Sigma Advisers's Liminal BioSciences Inc. Common Shares position peaked at $11K in Q1 2022.
  • 14 funds tracked by Wall St. Rank held Liminal BioSciences Inc. Common Shares as of Q4 2022.

Based on Two Sigma Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.